Equillium AI Stock Analysis
Want to see EQ full AI Analyst Report?
Equillium (EQ) AI Stock Analysis
Equillium
(NASDAQ:EQ)
The score is held back primarily by weak financial performance (zero TTM revenue, ongoing losses, and sustained cash burn) and bearish technicals (price below major moving averages with negative MACD). Offsetting these risks, recent corporate events strengthen the outlook by advancing the EQ504 program and extending the cash runway into 2029, while valuation remains hard to assess favorably due to negative earnings and no dividend support.
Equillium (EQ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $90.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 531.91K
- Price to Earnings (P/E)
- -5.5
- Beta (1Y)
- -0.47
- Revenue Growth
- -100.00%
- EPS Growth
- 64.23%
- Country
- US
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Equillium Business Overview & Revenue Model
Company Description
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficien...
Equillium Financial Statement Overview
Summary
Overall financials are weak: TTM revenue fell to zero with continued sizeable net losses (~$18M) and heavy ongoing cash burn (FCF ~-$20M). The balance sheet is the main offsetting strength with very low leverage (~$0.6M debt vs ~$56M equity), but persistent losses can continue eroding equity over time.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 41.09M | 36.08M | 15.76M | 0 |
| Gross Profit | -47.00K | -116.00K | 41.09M | 36.08M | 15.76M | -72.00K |
| EBITDA | -18.32M | -22.28M | -7.57M | -12.14M | -61.26M | -37.91M |
| Net Income | -18.01M | -22.40M | -8.07M | -13.34M | -62.43M | -38.98M |
Balance Sheet | ||||||
| Total Assets | 58.67M | 31.89M | 25.60M | 50.53M | 78.42M | 85.41M |
| Cash, Cash Equivalents and Short-Term Investments | 57.16M | 30.28M | 22.57M | 40.87M | 71.02M | 80.71M |
| Total Debt | 584.00K | 719.00K | 384.00K | 824.00K | 10.19M | 11.79M |
| Total Liabilities | 2.65M | 3.29M | 6.54M | 27.96M | 46.48M | 18.90M |
| Stockholders Equity | 56.02M | 28.60M | 19.06M | 22.57M | 31.94M | 66.50M |
Cash Flow | ||||||
| Free Cash Flow | -20.09M | -22.79M | -19.11M | -21.83M | -9.01M | -32.14M |
| Operating Cash Flow | -19.97M | -22.75M | -19.03M | -21.78M | -8.73M | -32.08M |
| Investing Cash Flow | -106.00K | 4.46M | 13.81M | -4.76M | 18.68M | 27.41M |
| Financing Cash Flow | 65.74M | 30.43M | 164.00K | -9.23M | -1.22M | 31.06M |
Equillium Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EQ, the sentiment is Negative. The current price of 1.42 is above the 20-day moving average (MA) of 1.36, below the 50-day MA of 1.63, and below the 200-day MA of 2.09, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.60 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EQ.
Equillium Risk Analysis
Equillium disclosed 86 risk factors in its most recent earnings report. Equillium reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksEquillium Peers Comparison
Overall Rating
- EQ48Neutral
NRXP46Neutral
HYFT45Neutral
STRO42Neutral
PRLD38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| EQ | 48Neutral | $92.26M | -5.54 | -41.15% | ― | -100.00% | 64.23% |
| NRXP | 46Neutral | $103.01M | -3.28 | 168.68% | ― | ― | 67.07% |
| HYFT | 45Neutral | $49.00M | -4.02 | -144.31% | ― | -26.89% | 56.50% |
| STRO | 42Neutral | $168.63M | -0.59 | 185.30% | ― | -56.25% | 30.97% |
| PRLD | 38Underperform | $300.06M | -4.78 | -75.35% | ― | 220.34% | 55.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EQ | Equillium | 1.42 | 0.58 | 69.05% | |
| NRXP | Nrx Pharmaceuticals, Inc. | 2.44 | -0.15 | -5.79% | |
| STRO | Sutro Biopharma | 10.26 | 0.97 | 10.44% | |
| HYFT | Mindwalk Holdings Corp. | 1.03 | -0.62 | -37.58% | |
| PRLD | Prelude Therapeutics, Inc. | 3.78 | 2.27 | 150.33% |
Equillium Corporate Events
Equillium advances EQ504 trial and extends cash runway
PositiveOn October 26, 2026, Equillium reported dosing the first subject in its Phase 1 clinical trial of EQ504 in Australia, a randomized, double-blind, placebo-controlled study in about 70 healthy volunteers evaluating safety, tolerability, pharmacokinetic...
Equillium Advances EQ504 With Phase 1 Trial Clearance
PositiveOn October 5, 2026, Equillium, Inc. announced that it had secured Human Research Ethics Committee approval and Therapeutic Goods Administration clearance in Australia for a Phase 1 clinical trial of its oral candidate EQ504, with first dosing of heal...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026